Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2016 | 1 |
2017 | 1 |
2019 | 1 |
2020 | 1 |
2022 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
J Clin Oncol. 2023 Apr 1;41(10):1888-1897. doi: 10.1200/JCO.22.00437. Epub 2022 Dec 1.
J Clin Oncol. 2023.
PMID: 36455187
Clinical Trial.
Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?
Wermke M, Gloaguen S, Platzbecker U.
Wermke M, et al. Among authors: gloaguen s.
Curr Hematol Malig Rep. 2015 Sep;10(3):329-33. doi: 10.1007/s11899-015-0276-z.
Curr Hematol Malig Rep. 2015.
PMID: 26126601
Review.
Item in Clipboard
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L.
Kubasch AS, et al. Among authors: gloaguen s.
Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7.
Leukemia. 2022.
PMID: 36071100
Free PMC article.
Item in Clipboard
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U.
Francke S, et al. Among authors: gloaguen s.
Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23.
Leuk Lymphoma. 2017.
PMID: 27659716
No abstract available.
Item in Clipboard
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U.
Kubasch AS, et al. Among authors: gloaguen s.
Leukemia. 2020 Apr;34(4):1182-1186. doi: 10.1038/s41375-019-0645-z. Epub 2019 Dec 3.
Leukemia. 2020.
PMID: 31796915
Free PMC article.
Clinical Trial.
No abstract available.
Item in Clipboard
Cite
Cite